Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 3/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825584 | 0.88 | TDP1 (0.44) | CYP3A4MAPK1LMNACNR2TDP1 | |
| SCHEMBL13035554 | 0.86 | TAS1R3 (0.40) | CYP3A4MAPK1LMNACNR2CNR1 | |
| SCHEMBL14269010 | 0.86 | TAS1R3 (0.40) | CYP3A4MAPK1LMNACNR2CNR1 | |
| SCHEMBL13034816 | 0.86 | TAS1R3 (0.40) | CYP3A4MAPK1LMNACNR2CNR1 | |
| SCHEMBL14268998 | 0.84 | TAS1R3 (0.40) | CYP3A4MAPK1CNR2TDP1CNR1 | |
| SCHEMBL23613008 | 0.83 | CYP3A4 (0.37) | CYP3A4MAPK1LMNACNR2 | |
| SCHEMBL25927245 | 0.83 | CYP3A4 (0.37) | CYP3A4MAPK1LMNACNR2 | |
| SCHEMBL1399119 | 0.82 | LMNA (0.50) | CYP3A4MAPK1LMNATDP1CNR1 | |
| SCHEMBL25839087 | 0.81 | CYP3A4 (0.36) | CYP3A4MAPK1LMNACNR2TDP1 | |
| SCHEMBL12156779 | 0.81 | DPP7 (0.41) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6291620-B1 | Polymer synthesis | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-09-18 | — | — | US | claimed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-08-06 | — | — | US | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| US-20200038342-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | CATABASIS PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9586956-B2 | Isoquinoline and naphthyridine derivatives | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | GENENTECH, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8481750-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20120178734-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| US-20120178734-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| US-7977339-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100311649-A1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141330-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-7795265-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090118300-A1 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118300-A1 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators | CCKAR, CCKBR, GPR119 | CYP3A4 1362/4885MAPK1 702/4885LMNA 4724/4885 |
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | CYP3A4 3761/4885MAPK1 3879/4885LMNA 3607/4885 |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | CYP3A4 1639/4885MAPK1 3637/4885LMNA 1436/4885 |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | NQO1, NDUFC2, NDUFV2 | CYP3A4 84/4885MAPK1 2796/4885LMNA 992/4885 |
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885MAPK1 3145/4885LMNA 2845/4885 |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | NDUFAB1, ATG7, NLN | CYP3A4 1864/4885MAPK1 4178/4885LMNA 2734/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885MAPK1 3145/4885LMNA 2845/4885 |
| US-20120178734-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | ARG1, COL14A1, HPGDS | CYP3A4 1846/4885MAPK1 1269/4885LMNA 3234/4885 |
| US-20100311649-A1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | CCKAR, CCKBR, GPR119 | CYP3A4 1362/4885MAPK1 702/4885LMNA 4724/4885 |
| US-20180208577-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885MAPK1 3145/4885LMNA 2845/4885 |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ACVR1, ACVRL1, ALK | CYP3A4 1485/4885MAPK1 1109/4885LMNA 1500/4885 |
| US-20200038342-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | ATG7, ATG4A, SLC27A1 | CYP3A4 3185/4885MAPK1 3810/4885LMNA 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.